Grant: Operating Grant: CAG Gastroenterology/Nutrition - Upper GI - AstraZeneca
McMaster University
$44,965.00
Non Dietary treatment for gliadin-induced enteropathy
EF 2010-11
Résumé
Celiac disease (CD) is a common and complex illness in Gastroenterology. In CD, gluten contained in cereals, causes damage of the lining of the gut wall leading to malabsorption of nutrients.
Patients with celiac disease may develop diarrhea, irritable bowel syndrome symptoms and, particularly in adults, often present with osteoporosis, anemia, infertility or neurological and psychiatric symptoms. Awareness among physicians is growing due to highly accurate blood tests. Recent evidence suggests a rising incidence of CD. Young adults today are four times more likely to develop CD than fifty years ago. Environmental factors such as early life and widespread gluten exposure, intestinal infections and short duration of breast-feeding, have been proposed to have a role in CD.
The cornerstone treatment of CD remains a strict gluten-free diet. This nutritional regime is demanding, and relapses are common because of social isolation, financial issues, or restriction of food diversity.
The main goal of this proposal is to explore and develop novel pharmacological therapies for celiac disease and gluten intolerance. We will test these therapies in animal models of gluten sensitivity established in my lab. The therapies are based on two complementary strategies. First, gluten is incompletely digested in humans, leading to the production of toxic fragments that cause intestinal damage in susceptible persons. We have engineered a bacterium, Lactococcus lactis, a common resident in our gut, to deliver enzymes that degrade the toxic fragments of gluten in the intestine. The second approach will investigate the efficacy of a polymer that binds to gliadin in the gut lumen, to prevent gluten toxicity when administered in a complex food mixture.
The development of therapies that allow occasional exposure to low levels of gluten in adults with CD and gluten intolerance is expected to decrease the burden of disease and improve patients' quality of life.
Programme
Operating Grant: CAG Gastroenterology/Nutrition - Upper GI - AstraZeneca
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
229285
Name
Verdu Elena F
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
AstraZeneca Canada Inc.; Canadian Association of Gastroenterology (Oakville, Ontario)
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Operating Grant: Gastroenterology / Nutrition (2010)
Projecttitle
Non Dietary treatment for gliadin-induced enteropathy
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$44,965
Cihrequipment2
$0
Programname2
Operating Grant: CAG Gastroenterology/Nutrition - Upper GI - AstraZeneca
Keyworddelim
Upper Gastrointestinal Inflammation
Abstract
Celiac disease (CD) is a common and complex illness in Gastroenterology. In CD, gluten contained in cereals, causes damage of the lining of the gut wall leading to malabsorption of nutrients.
Patients with celiac disease may develop diarrhea, irritable bowel syndrome symptoms and, particularly in adults, often present with osteoporosis, anemia, infertility or neurological and psychiatric symptoms. Awareness among physicians is growing due to highly accurate blood tests. Recent evidence suggests a rising incidence of CD. Young adults today are four times more likely to develop CD than fifty years ago. Environmental factors such as early life and widespread gluten exposure, intestinal infections and short duration of breast-feeding, have been proposed to have a role in CD.
The cornerstone treatment of CD remains a strict gluten-free diet. This nutritional regime is demanding, and relapses are common because of social isolation, financial issues, or restriction of food diversity.
The main goal of this proposal is to explore and develop novel pharmacological therapies for celiac disease and gluten intolerance. We will test these therapies in animal models of gluten sensitivity established in my lab. The therapies are based on two complementary strategies. First, gluten is incompletely digested in humans, leading to the production of toxic fragments that cause intestinal damage in susceptible persons. We have engineered a bacterium, Lactococcus lactis, a common resident in our gut, to deliver enzymes that degrade the toxic fragments of gluten in the intestine. The second approach will investigate the efficacy of a polymer that binds to gliadin in the gut lumen, to prevent gluten toxicity when administered in a complex food mixture.
The development of therapies that allow occasional exposure to low levels of gluten in adults with CD and gluten intolerance is expected to decrease the burden of disease and improve patients' quality of life.
Competitiondate
201011
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Verdu, Elena F
Approvedterm
2 ans 0 mois
Cihrcontribution2
Patient Oriented Research~ $44,965~ $0~